Relationship of radiographic progression status to low disease activity in patients with PsA receiving secukinumab treatment for 2 years

Journal article

Objective: To examine relationships between radiographic progression and achievement of low disease activity (LDA) or remission at week 104 in patients with PsA receiving secukinumab. Methods: This post hoc analysis included data from patients with active PsA enrolled in the phase 3 FUTURE 5 study (NCT02404350). Patients were pooled by treatment received at week 104 (secukinumab 300 mg with loading dose [LD], secukinumab 150 mg with LD or secukinumab 150 mg without LD) and grouped by radiographic progression status. Radiographic progression was defined as change from baseline to week 104 in van der Heijde modified Total Sharp Score >0.5. Efficacy was assessed by achievement of minimal disease activity (MDA), very low disease activity (VLDA) and Disease Activity Index for PsA (DAPSA) LDA or remission. Demographics and clinical characteristics associated with radiographic progression at week 104 were identified by logistic regression analyses. Results: Of the 541 patients included in this analysis, 457 (84.5%) were radiographic non-progressors and 84 (15.5%) were radiographic progressors. Higher proportions of non-progressors achieved MDA, VLDA and DAPSA LDA and remission at week 104 than progressors. Radiographic progression at week 104 was associated with older age and higher baseline high-sensitivity CRP level, whereas non-progression was associated with 300 mg secukinumab (vs 150 mg secukinumab without LD), no prior exposure to tumour necrosis factor inhibitors and lower BMI. Conclusion: Patients without radiographic progression through 2 years of secukinumab treatment had greater achievement of LDA states at week 104 than patients with radiographic progression. Trial registration: ClinicalTrials.gov; NCT02404350.

Authors: Mease, PJ; Coates, LC; Gaillez, C; Shew, A; Bao, W

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Oxford University Press
• Journal: Rheumatology
• Volume: 65
• Issue: 1
• Pages: keaf488
• Article number: keaf488
• Publication date: 2025-09-18
• Acceptance date: 2025-08-01
• DOI: 10.1093/rheumatology/keaf488
• EISSN: 1462-0332
• ISSN: 1462-0324
• Language: English
• Keywords: secukinumab; radiographic progression; PsA